The popularity of copyright’s blockbuster initially sparked a boom for pharma, however recent shifts present a uncertain outlook for those considering a stake. Generic competitors are reducing revenue, and ongoing legal battles add more complexity to the landscape. While some companies may still gain from related offerings, the overall direction… Read More